(Press-News.org) A combination of remdesivir, a drug currently approved in the United States for treating COVID-19 patients, and repurposed drugs for hepatitis C virus (HCV) was 10 times more effective at inhibiting SARS-CoV-2, the virus that causes COVID-19.
The combination therapy points a way toward a treatment for unvaccinated people who become infected, as well as for vaccinated people whose immunity has waned, for example due to the emergence of virus variants that escape this immune protection.
Four HCV drugs--simeprevir, vaniprevir, paritaprevir, and grazoprevir--in combination with remdesivir boosted the efficacy of remdesivir by as much as 10-fold, the researchers reported today in Cell Reports. The research team included scientists from Icahn School of Medicine at Mount Sinai, the University of Texas at Austin, and Rensselaer Polytechnic Institute (RPI).
Remdesivir targets a range of viruses and was originally developed over a decade ago to treat hepatitis C and a cold-like virus called respiratory syncytial virus (RSV). During the Ebola outbreak, Remdesivir was tested in clinical trials and found to be safe and effective for patients. Early in the pandemic, it was seen as a good therapy for COVID-19 but did not live up to its early promise in studies.
The research team performed protein binding and viral replication studies on SARS-CoV-2, the virus that causes COVID-19, using remdesivir and 10 hepatitis C drugs, some of which are already approved by the Food and Drug Administration.
RPI team had previously identified "striking similarity" between protease structures, or enzymes that are essential for coronaviral replication, in SARS-CoV-2 and HCV. The similarity raised the possibility that existing drugs which bind to and block the hepatitis C protease would have the same effect against SARS-CoV-2.
Using a supercomputer to model how drugs bind to viral proteins, the RPI researchers predicted that the 10 HCV drugs could bind snugly to the SARS-CoV-2 Main protease, named Mpro. In addition, they showed that seven of these drugs actually inhibited the SARS-CoV-2 protease. The research team at Icahn Mount Sinai then tested whether these seven drugs would inhibit SARS-CoV-2 virus replication in monkey and human cells grown in culture. In subsequent experiments the researchers were surprised to find that the four HCV drugs inhibited a different SARS-CoV-2 protease, known as PLpro. This observation proved to be very important. When each of the seven HCV drugs were tested in combination with remdesivir, only the four drugs that unexpectedly targeted PLpro boosted the efficacy of remdesivir, by as much as 10-fold.
Adolfo Garcia-Sastre, PhD, one of the authors on the paper, Irene and Dr. Arthur M. Fishberg Professor of Medicine. and Director of the Global Health and Emerging Pathogens Institute at Icahn Mount Sinai, said, "Combined use of remdesivir with PLpro inhibitors for the treatment of COVID-19 could be a game changer for patients with COVID-19 who are not vaccinated. It could also reduce the possibility of selecting SARS-CoV-2-resistant viruses."
"The identification of PLpro as an antiviral target that has a synergistic effect in combination with remdesivir is a very important finding. We hope this work will encourage the development of specific SARS-CoV-2 PLpro inhibitors for inclusion in combination therapies to produce a highly effective antiviral cocktail that may potentially prevent the rise of resistance mutations," said Kris White, PhD, Assistant Professor of Microbiology at Icahn Mount Sinai.
"Because these HCV drugs are already approved for use and their potential side effects are known, such a combination therapy could be tested in humans more quickly than for a new drug," said Robert M. Krug, PhD, Professor Emeritus of Molecular Biosciences at The University of Texas at Austin and co-corresponding author of the paper.
One big drawback of remdesivir is that it must be administered intravenously, limiting its use to patients already admitted to the hospital. "Our goal is to develop a combination of oral drugs that can be administered to outpatients before they are sick enough to require hospitalization," said Krug. "The HCV drugs that enhance remdesivir's antiviral activity are oral drugs. It is important to identify oral drugs that inhibit the SARS-CoV-2 polymerase in order to develop an effective outpatient treatment."
"Nearly 3 million people have died worldwide from COVID-19. There are situations where the vaccine isn't the best option and it would be helpful to have orally available antivirals," said Gaetano Montelione, PhD, a member of the Rensselaer Center for Biotechnology and Interdisciplinary Studies (CBIS). "Here we see a promising synergy that, if confirmed through additional research and clinical trials, could provide a new antiviral to combat COVID-19."
INFORMATION:
View visual assets here: https://www.dropbox.com/sh/bgn6os7iquew8em/AAAhnWtt1x7__UqW6v7jis01a?dl=0
The other participants in this research are Catherine Royer, Theresa A. Ramelot, Thomas B. Acton, and Balasubramanian Harish at RPI; and Romel Rosales, Elena Moreno, Thomas Kehrer, and Lisa Miorin at Icahn Mount Sinai.
This research was supported by the National Institutes of Health, the RPI Center for Computational Innovations, the National Institute of Allergy and Infectious Diseases, the Defense Advanced Research Projects Agency, the Department of Defense, the JPB Foundation and the Open Philanthropy Project.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care--from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Nearly 80 percent of higher education faculty report dealing with student mental health issues—issues that more than 90 percent of faculty believe have worsened or significantly worsened during the pandemic, according to a new nationwide survey led by a Boston University mental health researcher.
"The vast majority of faculty members, myself included, are not trained mental health professionals, but we have a role to play in supporting student well-being," says survey principal investigator Sarah Ketchen Lipson, a BU School of Public Health assistant professor of health law, policy, and management. "These data underscore a real opportunity to better equip faculty with knowledge ...
UCLA materials scientists have developed a class of optical material that controls how heat radiation is directed from an object. Similar to the way overlapping blinds direct the angle of visible light coming through a window, the breakthrough involves utilizing a special class of materials that manipulates how thermal radiation travels through such materials.
Recently published in Science, the advance could be used to improve the efficiency of energy-conversion systems and enable more effective sensing and detection technologies.
"Our goal was to show that we could effectively beam thermal radiation -- the heat all objects emanate as electromagnetic waves -- ...
By translating the pattern of interconnections between nature's food chains to industrial networks, researchers at Texas A&M University have delineated guidelines for setting up successful industrial communities. The researchers said this guidance can facilitate economic growth, lower emissions and reduce waste while simultaneously ensure that partnering industries can recover from unexpected disturbances.
"Industries can often partner up to exchange byproducts and over time these industries might form bigger communities. While these networks sound quite beneficial to all industry partners within the community, they are not always successful," said Dr. Astrid Layton, assistant professor in the J. Mike Walker' ...
"This finding suggests that higher education does not influence brain aging" says Lars Nyberg from Umeå University in Sweden, first author of the study and also a part of the Lifebrain consortium.
Brains shrink at the same rate
All brains shrink with age, and the dominant view has been that more education slows the rate of shrinking. However, the evidence has been inconclusive because studies have not been able to track the rate of change over time. Until now.
Measured brain shrinkage over time
The researchers measured brain aging by measuring the ...
EUGENE, Ore. -- April 27, 2021 -- The addition of meat alternatives such as poultry and fish is not reducing the global production and consumption of energy-gobbling land-based meats, according to new research.
That conclusion comes from an analysis of 53 years of international data by University of Oregon sociologist Richard York, who focuses on energy consumption in relationship to economic issues such as power and inequalities, and politics. His findings published April 26 in the journal Nature Sustainability.
"If you have increases in the production of poultry and fish, it doesn't tend to compete with or suppress other meat source consumption," York said. "It would be great if more ...
Shopping habits and escalating consumption of many consumers are inflicting a heavy environmental toll, and while the majority of customers seem hesitant to act "green" on their own, companies are increasingly expected to implement effective eco-friendly tactics. But efforts to increase towel reuse at hotels, paperless adoption in the banking industry or "ugly" food consumption at grocery stores have been challenging.
As a result, millions of tons of cosmetically imperfect produce are wasted every year in the United States while about one billion trees worth of paper are thrown away. Electricity consumption ...
An international, multidisciplinary team that includes faculty members from The University of Texas at Arlington has published a paper in the journal Philosophical Psychology that wades into the debate about whether fish feel pain.
Their conclusion: while fish lack certain regions of the brain typically associated in humans with processing the unpleasantness of pain, this does not offer definitive proof that fish don't experience painful events.
There is a divide among contemporary scientists and philosophers on the issue of animal suffering, particularly in fish. Following the discovery of pain receptors in fish in the early 21st century, scientists developed behavioral experiments that seemed to show that fish ...
Rockville, Md. (April 27, 2021)--Deep heat creams widely used by athletes to soothe sore muscles may also boost performance when applied before exercise, according to new research presented virtually this week at the American Physiological Society's (APS) annual meeting at Experimental Biology 2021.
Researchers at Nanyang Technological University in Singapore studied a small group of male volunteers to determine the effects of deep heat cream on exercise endurance. Each volunteer participated in two trials--one where he applied a thin layer of a commercially available ...
Rockville, Md. (April 27, 2021)--Researchers from Wake Forest School of Medicine in North Carolina have demonstrated that a common diabetes drug inhibits the spread of Clostridioides difficile, or C. diff--a potentially life-threatening infection commonly acquired during hospital stays. The team will present their work virtually at the American Physiological Society's (APS) annual meeting at Experimental Biology 2021.
C. diff is the most common hospital-acquired infection in the U.S. It starts in the intestines, often after a course of antibiotics. The Centers for Disease Control and Prevention categorizes the bacteria C. diff as a public health threat that "require[s] urgent and aggressive action." In 2017, ...
Rockville, Md. (April 27, 2021)--The popular herbicide Roundup® has been in the news because of concerns its main ingredient, glyphosate, might cause cancer. Now researchers from Florida Atlantic University (FAU) are evaluating the pesticide for potential neurological impacts. This week, the scientists will present their work virtually at the American Physiological Society's (APS) annual meeting at Experimental Biology 2021.
The roundworm Caenorhabditis elegans (C. elegans) is a microscopic worm that lives in soil and feeds on bacteria. Scientists have studied it extensively since the 1960s to better understand fundamental physiological processes of the animal kingdom. Because roughly 38% of its genes have counterparts in humans, findings ...
